Thinking about this further, why did the government make this change to pathology and radiology without any industry consultation when a formal Medicare review is already underway and nearing conclusion?
Could it be because they already know that the outcome of the clinician-led Medicare review process isn't likely to bring them material cost savings to help the budget bottom line?
And that perhaps there isn't as much material excess and waste in the health system as they had initially thought?
An earlier article on this topic is below:
http://www.businessspectator.com.au/article/2015/11/2/asx/why-healthcare-investors-have-jitters
Thinking about this further, why did the government make this...
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SHL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$26.20 |
Change
0.310(1.20%) |
Mkt cap ! $12.91B | |||
| Open | High | Low | Value | Volume |
| $25.86 | $26.27 | $25.79 | $23.17M | 887.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3120 | $26.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $26.30 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| SHL (ASX) Chart |
